Skip to main content
Top
Published in: Infection 5/2019

01-10-2019 | Hepatitis B | Original Paper

Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy

Authors: Tommaso Stroffolini, Evangelista Sagnelli, Caterina Sagnelli, Filomena Morisco, Sergio Babudieri, Caterina Furlan, Mario Pirisi, Maurizio Russello, Antonina Smedile, Mariantonietta Pisaturo, Piero Luigi Almasio

Published in: Infection | Issue 5/2019

Login to get access

Abstract

Background

The epidemiology of hepatocellular carcinoma (HCC) is characterized by a dynamical temporal trend of well-established and emerging risk factors.

Methods

We evaluated the temporal trend of aetiological factors of HCC over the last two decades in Italy. HCC cases were recruited from two previously published national studies in 1996 and in 2008 and HCC cases were also enlisted from two national surveys in 2001 and in 2014 enrolling consecutive subjects with chronic liver disease (CLD) referring to more than 80 liver units scattered all over the country for a 6-month period.

Results

Out of the 9997 subjects with CLD recruited in 2001 and the 2408 recruited in 2014, 3.3% and 5.7% (P < 0.001), respectively, had HCC. The temporal trend of HBsAg −/HCV + HCC cases significantly linearly decreased from 71.1% in 1996 to 57.2% in 2014 (P < 0.001). Conversely, that of virus-negative cases significantly linearly increased from 12.1% to 28.3% (P < 0.001). The proportion of HBV-related HCC cases showed a steady low rate, reflecting the reduced endemicity of the infection in Italy. The proportion of HCC with compensated cirrhosis (i.e., Child–Pugh A) linearly increased over time from 55.6% in 1996 to 76.0% in 2014 (P < 0.001) reflecting the growing effectiveness of semi-annual ultrasound surveillance for early detection of HCC.

Conclusion

In conclusion, with decreasing viral aetiology, an overall decrease in the incidence of HCC might be expected in the future. The proportion of metabolic diseases is conversely increasing being considered as an aetiology. The growing prevalence of metabolic disorders in the general population may further increase this trend in the years to come.
Literature
1.
go back to reference Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009;27:80–92.PubMed Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma–epidemiological trends and risk factors. Dig Dis. 2009;27:80–92.PubMed
2.
go back to reference Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.CrossRef Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.CrossRef
3.
go back to reference Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRef
4.
go back to reference Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–9.CrossRef Bertuccio P, Turati F, Carioli G, Rodriguez T, La Vecchia C, Malvezzi M, Negri E. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol. 2017;67:302–9.CrossRef
5.
go back to reference Yang JD, Mohamed EA, Aziz AOA, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–11.CrossRef Yang JD, Mohamed EA, Aziz AOA, Shousha HI, Hashem MB, Nabeel MM, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–11.CrossRef
6.
go back to reference Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981;305:1371–4.CrossRef Lebrec D, Poynard T, Hillon P, Benhamou JP. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med. 1981;305:1371–4.CrossRef
7.
go back to reference Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med. 1995;123:280–7.CrossRef Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: a meta-analysis. Ann Intern Med. 1995;123:280–7.CrossRef
8.
go back to reference Quintero E, Ginés P, Arroyo V, Rimola A, Bory F, Planas R, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet. 1985;8429:611–2.CrossRef Quintero E, Ginés P, Arroyo V, Rimola A, Bory F, Planas R, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet. 1985;8429:611–2.CrossRef
9.
go back to reference Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti A, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol. 2015;63:1118–25.CrossRef Lampertico P, Invernizzi F, Viganò M, Loglio A, Mangia G, Facchetti A, et al. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: a 12-year prospective cohort study. J Hepatol. 2015;63:1118–25.CrossRef
10.
go back to reference Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella M, et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis a retrospective study. Hepatology. 2007;45:579–87.CrossRef Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella M, et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis a retrospective study. Hepatology. 2007;45:579–87.CrossRef
11.
go back to reference Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–14.CrossRef Sangiovanni A, Del Ninno E, Fasani P, De Fazio C, Ronchi G, Romeo R, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–14.CrossRef
12.
go back to reference Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.CrossRef Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61:191–9.CrossRef
13.
go back to reference Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9997 cases. J Med Virol. 2005;75:522–7.CrossRef Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9997 cases. J Med Virol. 2005;75:522–7.CrossRef
14.
go back to reference Sagnelli E, Stroffolini T, Sagnelli C, Smedile A, Morisco F, Furlan C, et al. Epidemiological and clinical scenario of chronic liver diseases in Italy: data from a multicenter nationwide survey. Dig Liver Dis. 2016;48:1066–71.CrossRef Sagnelli E, Stroffolini T, Sagnelli C, Smedile A, Morisco F, Furlan C, et al. Epidemiological and clinical scenario of chronic liver diseases in Italy: data from a multicenter nationwide survey. Dig Liver Dis. 2016;48:1066–71.CrossRef
15.
go back to reference Strofolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiramonte M, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol. 1998;29:942–4.CrossRef Strofolini T, Andreone P, Andriulli A, Ascione A, Craxi A, Chiramonte M, et al. Characteristics of hepatocellular carcinoma in Italy. J Hepatol. 1998;29:942–4.CrossRef
16.
go back to reference Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini M, Iavarone MA, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Lver Dis. 2011;43:875–80. Stroffolini T, Trevisani F, Pinzello G, Brunello F, Tommasini M, Iavarone MA, et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig Lver Dis. 2011;43:875–80.
17.
go back to reference Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23:1025–9.CrossRef Becker U, Deis A, Sørensen TI, Grønbaek M, Borch-Johnsen K, Müller CF, et al. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology. 1996;23:1025–9.CrossRef
18.
go back to reference McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–36.CrossRef McCullough AJ, O’Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2022–36.CrossRef
19.
go back to reference Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D’Errico A, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27:979–85.CrossRef Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D’Errico A, et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997;27:979–85.CrossRef
20.
go back to reference Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRef Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–30.CrossRef
21.
go back to reference Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Italian Liver Cancer (ITA.LI.CA) Group, et al. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. Liver Int. 2013;33:1420–7.CrossRef Cazzagon N, Trevisani F, Maddalo G, Giacomin A, Vanin V, Pozzan C, Italian Liver Cancer (ITA.LI.CA) Group, et al. Rise and fall of HCV-related hepatocellular carcinoma in Italy: a long-term survey from the ITA.LI.CA centres. Liver Int. 2013;33:1420–7.CrossRef
22.
go back to reference Chiaramonte M, Stroffolini T, Lorenzoni U, Minniti F, Conti S, Floreani A, et al. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol. 1996;24:129–34.CrossRef Chiaramonte M, Stroffolini T, Lorenzoni U, Minniti F, Conti S, Floreani A, et al. Risk factors in community-acquired chronic hepatitis C virus infection: a case-control study in Italy. J Hepatol. 1996;24:129–34.CrossRef
23.
go back to reference Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79–84.CrossRef Andriulli A, Stroffolini T, Mariano A, Valvano MR, Grattagliano I, Ippolito AM, et al. Declining prevalence and increasing awareness of HCV infection in Italy: a population-based survey in five metropolitan areas. Eur J Intern Med. 2018;53:79–84.CrossRef
24.
go back to reference Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Italian Liver Cancer (ITA.LI.CA) group, et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2017;37:259–70.CrossRef Bucci L, Garuti F, Lenzi B, Pecorelli A, Farinati F, Giannini EG, Italian Liver Cancer (ITA.LI.CA) group, et al. The evolutionary scenario of hepatocellular carcinoma in Italy: an update. Liver Int. 2017;37:259–70.CrossRef
25.
go back to reference Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–38.CrossRef Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, HCC-NAFLD Italian Study Group, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63:827–38.CrossRef
26.
go back to reference Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther. 2017;46:856–63.CrossRef Pais R, Fartoux L, Goumard C, Scatton O, Wendum D, Rosmorduc O, et al. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Aliment Pharmacol Ther. 2017;46:856–63.CrossRef
27.
go back to reference Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005;37:622–7.CrossRef Stroffolini T. The changing pattern of hepatitis B virus infection over the past three decades in Italy. Dig Liver Dis. 2005;37:622–7.CrossRef
28.
go back to reference Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRef Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.CrossRef
29.
go back to reference Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.CrossRef Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol. 2012;56:1384–91.CrossRef
30.
go back to reference Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31.CrossRef Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14:124–31.CrossRef
31.
go back to reference Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.CrossRef Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.CrossRef
32.
go back to reference Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52.CrossRef Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology. 2005;42:44–52.CrossRef
Metadata
Title
Decreasing role of HCV and HBV infections as aetiological factors of hepatocellular carcinoma in Italy
Authors
Tommaso Stroffolini
Evangelista Sagnelli
Caterina Sagnelli
Filomena Morisco
Sergio Babudieri
Caterina Furlan
Mario Pirisi
Maurizio Russello
Antonina Smedile
Mariantonietta Pisaturo
Piero Luigi Almasio
Publication date
01-10-2019
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 5/2019
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-019-01308-3

Other articles of this Issue 5/2019

Infection 5/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.